Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient…